Soligenix to receive $1.2 m in non-dilutive funding through new jersey technology business tax certificate transfer program

Princeton, n.j. , nov. 15, 2022 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received preliminary approval for a tax credit from the new jersey economic development authority's (njeda) new jersey technology business tax certificate transfer program.
SNGX Ratings Summary
SNGX Quant Ranking